Articles tagged with: Dacogen
Featured, Headline, News »
Results of a retrospective analysis indicate that stem cell transplantation does not significantly improve survival for higher-risk myelodysplastic syndromes patients compared to treatment with Vidaza or Dacogen.
As a result, the researchers who conducted the analysis conclude that treatment with Vidaza (azacitidine) or Dacogen (decitabine) is an “adequate alternative” for myelodysplastic syndromes (MDS) patients ineligible for stem cell transplantation. They also recommend that transplant-eligible patients be treated with Vidaza or Dacogen while waiting for a stem cell donor.
The findings were presented at the 2011 meeting of…
News »
Vidaza May Be More Cost Effective Than Dacogen – Results of a recent analysis indicate that Vidaza (azacitidine) may be more cost-effective than Dacogen (decitabine) for myelodysplastic syndromes (MDS) patients. The analysis makes use of U.S. health care treatment costs and assumptions about treatment outcomes based on previously published clinical trial results. The total of all health care costs for a patient treated for two years with Vidaza is estimated to be $150,322, compared to $166,212 for Dacogen. The analysis was sponsored by Celgene, the manufacturer of Vidaza. For more information, please see the analysis in the journal Leukemia & Lymphoma (abstract).
Free Conference For MDS Patients And Their Families – On November 12, the MDS Foundation will host a free one-day conference for MDS patients and their families in Philadelphia. The conference will start at 10 a.m. with a patient support group discussion. In the afternoon, new therapies and treatment options for MDS will be presented and discussed. Complimentary breakfast and lunch will be served. For more information, please see the MDS Foundation website.
Webinar: MDS And Health Insurance Coverage – On November 17, the Aplastic Anemia & MDS International Foundation (AA&MDSIF) is hosting a webinar to explain health insurance coverage rules to MDS patients and their families. The webinar, which starts at 3 p.m. ET, will also include information about prescription and co-pay assistance programs that may be of interest to MDS patients. Participants will have the opportunity to ask questions at the end of the webinar. For more information or to register, please see the AA&MDSIF website.
For a more detailed listing of MDS-related events, please check the MDS Beacon Events Calendar.
Headline, News »
Dr. Mikkael Sekeres, a myelodysplastic syndromes expert and researcher at the Cleveland Clinic, recently created a list of guidelines for the treatment of lower-risk myelodysplastic syndromes patients.
He recommended that patients with low red blood cell counts (anemia) be treated with red blood cell-stimulating agents, which produced response rates of 40 percent in these patients.
For patients who do not respond to this treatment or have other low blood cell counts, he recommended treatment with Revlimid, Vidaza, Dacogen, and Anti-Thymocyte Globulin, which produced response rates of up to 67 percent.…
Headline, News »
Results of a recent analysis show that myelodysplastic syndromes patients treated with Dacogen received significantly fewer red blood cell or platelet transfusions compared to patients treated with Vidaza. Both patient groups had similar use of drugs that stimulate red blood cell production.
According to authors of the analysis, these findings suggest that myelodysplastic syndromes (MDS) patients treated with Dacogen may require fewer transfusions than patients treated with Vidaza.
However, they pointed out that further studies are needed to determine the impact of the treatments on transfusion dependence based on the…
Headline, News »
Results of a recent analysis show that treatment with the investigational drug Estybon may prolong survival in myelodysplastic syndromes patients who can no longer be effectively treated with Vidaza or Dacogen.
The results were presented at the 2010 meeting of the European Hematology Association (EHA) earlier this month.
Estybon (rigosertib, ON 01910.Na) is an anti-cancer drug that is being developed by Onconova Therapeutics. It works by inhibiting cell growth and selectively killing cancer cells.
Results of a previous study showed that Estybon may be effective in myelodysplastic syndromes (MDS) patients…